Adoptive T cell therapy for cancer in the clinic
Carl H. June
Carl H. June
Published June 1, 2007
Citation Information: J Clin Invest. 2007;117(6):1466-1476. https://doi.org/10.1172/JCI32446.
View: Text | PDF
Science in Medicine

Adoptive T cell therapy for cancer in the clinic

Abstract

The transfusion of lymphocytes, referred to as adoptive T cell therapy, is being tested for the treatment of cancer and chronic infections. Adoptive T cell therapy has the potential to enhance antitumor immunity, augment vaccine efficacy, and limit graft-versus-host disease. This form of personalized medicine is now in various early- and late-stage clinical trials. These trials are currently testing strategies to infuse tumor-infiltrating lymphocytes, CTLs, Th cells, and Tregs. Improved molecular biology techniques have also increased enthusiasm and feasibility for testing genetically engineered T cells. The current status of the field and prospects for clinical translation are reviewed herein.

Authors

Carl H. June

×

Figure 2

Suicide T cell therapy using adoptively transferred T cells.

Options: View larger image (or click on image) Download as PowerPoint
Suicide T cell therapy using adoptively transferred T cells. T cells can...
T cells can be engineered to express conditional suicide switches so that the T cells die when a drug is administered that activates the switch and causes apoptosis. Suicide constructs have been incorporated into allogeneic T cells that can be ablated in the event of GVHD and into autologous T cells that can be ablated in the event of toxicity or uncontrolled T cell proliferation.